TrialPloS one2023

Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.

Dmitry Lioznov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.